Cyclacel Pharmaceuticals Inc Stock Nasdaq
Equities
US23254L3069
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
Jun. 26 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Jun. 26 | Sector Update: Health Care Stocks Lower in Afternoon Trading | MT |
Financials (USD)
Sales 2024 * | 59.5K | Sales 2025 * | 50K | Capitalization | 2.56M |
---|---|---|---|---|---|
Net income 2024 * | -12M | Net income 2025 * | -14M | EV / Sales 2024 * | 43 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 51.2 x |
P/E ratio 2024 * |
-0.35
x | P/E ratio 2025 * |
-0.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.37% |
Latest transcript on Cyclacel Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 97-07-31 |
Paul McBarron
DFI | Director of Finance/CFO | 63 | 01-12-31 |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 20-12-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 83 | 06-02-28 | |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 20-12-16 |
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 97-07-31 |
1st Jan change | Capi. | |
---|---|---|
+20.03% | 126B | |
+23.61% | 118B | |
+23.26% | 27.87B | |
-18.07% | 20.95B | |
-15.13% | 16.92B | |
-14.81% | 16.18B | |
+9.78% | 14.84B | |
-46.10% | 14.79B | |
+52.34% | 14.08B |